This editorial describes the science behind a clinical trial of concizumab, an inhibitor of a naturally occurring anticoagulant, to treat hemophilia A and B.
No takes yet. Share an insight, caveat, or question.
Berg et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: